{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-036503","form_type":"8-K","ticker":"TRVI","cik":"0001563880","company_name":"Trevi Therapeutics, Inc.","filed_at":"2025-03-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.002452+00:00","generated_at":"2026-05-25T01:26:50.979540+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Trevi's Haduvio meets Phase 2a RIVER primary endpoint; 57% placebo-adjusted cough reduction","bullets":["Primary endpoint: 67% reduction from baseline in 24-hour cough frequency; 57% placebo-adjusted (p<0.0001).","84% of Haduvio patients had ≥30% reduction vs 29% placebo; early response at Day 7 (27 mg BID).","Severe cough subgroup (20+ coughs/hr): 66% reduction; moderate (10-19/hr): 68% reduction (p<0.0001).","Safety profile consistent with prior Haduvio trials; no treatment-emergent serious adverse events.","Trevi plans to discuss results with FDA and initiate next study after FDA input."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-036503","json":"https://secwatch.observer/filing/0000950170-25-036503.json","markdown":"https://secwatch.observer/filing/0000950170-25-036503.md","text":"https://secwatch.observer/filing/0000950170-25-036503.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1563880/000095017025036503/0000950170-25-036503-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1563880/000095017025036503/trvi-20250310.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T01:26:50.979540+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}